fatido/E+ via Getty Images
Corcept Therapeutics (NASDAQ:CORT) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in patients with amyotrophic lateral sclerosis did not meet the main goal.
The treatment failed to meet its primary goal of improved outcome in the